American cell and gene therapy company
President and CEO Sandy Macrae in 2018 Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc. ) is an American biotechnology company based in Brisbane , California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.[ 2]
History
The company was founded in 1995 in Richmond, California.[ 3] [ 3] [ 4] Edward Rebar became the senior vice president and chief technology officer of Sangamo.[ 5]
Research
Sangamo applies technology to treat haemophilia B and lysosomal storage diseases including mucopolysaccharidosis type I (Hurler Syndrome) and mucopolysaccharidosis type II (Hunter Syndrome). The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A . In its partnership with Pfizer in 2017,[ 6] Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease .[ 2] zinc finger gene editing technology.[ 7]
In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter syndrome .[ 8] [update] zinc finger nuclease were ongoing.[ 9]
Clinical trials
Sangamo's programs are a mix of wholly owned and partnered; major partners include Pfizer , Biogen , Sanofi , Takeda , and Kite (a Gilead company).[ 10] [ 2] [ 11] [ 12]
As of 2020 Sangamo had the following clinical trials underway in the US:
In February 2023, Sangamo Therapeutics announced that it would stop the late-stage development for the Phase 1/2 PRECIZN-1 study of BIVV003 its sickle cell drug.[ 20]
See also
References
^ a b c d e f "Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results" . Sangamo. February 22, 2023. Retrieved February 24, 2023 .^ a b c McConaghie, Andrew (May 17, 2017). "Sangamo and new gene therapy partner Pfizer lifted by FDA fast track" . Pharmaphorum . Retrieved October 1, 2018 . ^ a b "Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04" . Equities . September 8, 2018. Retrieved October 1, 2018 .^ Ledford, Heidi (September 5, 2018). "First test of in-body gene editing shows promise" . Nature . doi :10.1038/d41586-018-06195-6 . ISSN 0028-0836 . S2CID 92840885 . ^ "Sangamo Therapeutics appoints Edward Rebar as senior vice president" . Post Online Media . Richmond, California. July 16, 2018. Retrieved October 1, 2018 .^ "SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY | Pfizer" . www.pfizer.com . Retrieved April 22, 2020 .^ Renauer, Cory (September 6, 2018). "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?" . The Motley Fool . Retrieved October 1, 2018 . ^ Marchione, Marilyn (February 7, 2019). "Tests suggest scientists achieved 1st 'in body' gene editing" . AP News . Retrieved February 7, 2019 . ^ Staff (February 2, 2019). "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II" . ClinicalTrials.gov U.S. National Library of Medicine . Retrieved February 7, 2019 . ^ "SGMO.OQ - Sangamo Therapeutics Inc Profile | Reuters" . SGMO.OQ - Sangamo Therapeutics Inc Profile | Reuters . Retrieved July 28, 2020 .^ "Sangamo shares jump on Pfizer, Sanofi (and its own) gene, cell therapy updates" . FierceBiotech . Retrieved July 29, 2020 .^ "Exciting new Huntingtin lowering tool described - HDBuzz - Huntington's disease research news" . en.hdbuzz.net . Retrieved July 29, 2020 .^ "A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .^ "Dose-Ranging Study of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .^ "A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .^ "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .^ "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .^ "Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .^ "Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .^ "Sangamo shelves sickle cell therapy, joining rivals forced to rethink development plans" . Fierce Biotech . February 23, 2023. Retrieved February 24, 2023 .
External links
37°40′36″N 122°23′03″W / 37.67669°N 122.38421°W / 37.67669; -122.38421
.jpg)
